Longeveron to Present at the Annual Dawson James Small Cap Growth Conference

Rhea-AI Summary

Longeveron Inc. (NASDAQ: LGVN) announced that Chris Min, M.D., Ph.D., its Interim CEO and Chief Medical Officer, will present at the Dawson James Small Cap Growth Conference in Jupiter, Florida, on October 12, 2022. The presentation is scheduled for 4:30 – 4:55 p.m. ET, with a live webcast available on the company's website. Longeveron focuses on developing regenerative medicines, notably Lomecel-B™, which targets Hypoplastic Left Heart Syndrome, Alzheimer’s Disease, and Aging Frailty.

News Market Reaction – LGVN

-0.51%

-0.51% Session move

In the trading session that priced this news, LGVN declined 0.51%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that Chris Min, M.D., Ph.D., Interim Chief Executive Officer, and Chief Medical Officer at Longeveron, will present at the upcoming Dawson James Small Cap Growth Conference taking place in Jupiter, Florida from October 11-12, 2022.

Longeveron’s presentation will take place on Wednesday, October 12, 2022 from 4:30 – 4:55 p.m. ET. A live webcast of the presentation can be accessed by visiting “Events & Presentations” in the Investors section of Longeveron’s website at https://www.longeveron.com/. A replay of the webcast will be available shortly following the conference.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has a multi-modal mechanism of action that is pro-vascular, pro-regenerative, and anti-inflammatory, promoting tissue repair and healing with broad potential applications across a spectrum of disease areas. Longeveron is advancing Lomecel-B™ through clinical trials in three indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s Disease, and Aging Frailty. Additional information about the Company is available at www.longeveron.com.

Investor Contact:

Elsie Yau
Stern IR, Inc.
212-698-8700
elsie.yau@sternir.com  

FAQ

When is Longeveron's presentation at the Dawson James Small Cap Growth Conference?

Longeveron's presentation is scheduled for October 12, 2022, from 4:30 – 4:55 p.m. ET.

Who is presenting for Longeveron at the conference?

Chris Min, M.D., Ph.D., the Interim CEO and Chief Medical Officer, will present for Longeveron.

How can I watch Longeveron's presentation?

You can access the live webcast of Longeveron's presentation in the 'Events & Presentations' section of their website.

What is Lomecel-B™ developed by Longeveron?

Lomecel-B™ is an allogeneic medicinal signaling cell therapy targeting various health issues, including Hypoplastic Left Heart Syndrome and Alzheimer's Disease.

What are the key medical areas Longeveron is focusing on?

Longeveron is focusing on Hypoplastic Left Heart Syndrome, Alzheimer’s Disease, and Aging Frailty through its clinical trials.